In this week’s video, Dr. Brian G.M. Durie discusses the NCCN’s recent endorsement of the IMWG New Response Criteria, which advocates MRD testing for myeloma.

BOTTOM LINE:
NCCN did approve MRD testing for some myeloma patients, which is a positive step forward.

Have a question? Submit it to [email protected]

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
China Visit Strengthens Ongoing Collaborations to Improve the Lives of Myeloma Patients Worldwide
Next Post
NCCN endorses MRD testing: what does this mean for patients?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.